Checkpoints of TNF Gene Regulation
TNF基因调控的检查点
基本信息
- 批准号:7227536
- 负责人:
- 金额:$ 34.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-01 至 2010-04-30
- 项目状态:已结题
- 来源:
- 关键词:Adaptor Signaling ProteinAntibodiesAutoimmune ProcessAutoimmunityB-LymphocytesBindingBinding SitesBioinformaticsCD4 Positive T LymphocytesCalciumCell CountCell LineCellsCerebral MalariaCessation of lifeChromatinCommunicable DiseasesComplexConditionCytokine GeneDNADendritic CellsDeoxyribonuclease IDiseaseDistalEnhancersEnvironmentFunctional RNAFutureGene ExpressionGene Expression RegulationGenesGeneticGenetic TranscriptionGoalsHelper-Inducer T-LymphocyteHypersensitivityImmune responseIn VitroInflammatoryInflammatory Bowel DiseasesInterferon Type IIInterferonsInterleukin-10LeadLinkLipopolysaccharidesMediatingMediator of activation proteinMicroarray AnalysisModelingMolecularMusMycobacterium tuberculosisPathologyPhasePliabilityProcessProductionProteinsRNA InterferenceRecruitment ActivityRegulationRegulatory ElementResearchResistanceRetroviral VectorRheumatoid ArthritisRoleSeptic ShockSignal PathwaySignal Transduction PathwaySignaling MoleculeSiteSpecificityStaphylococcal Enterotoxin BStimulusT-LymphocyteTNF geneTestingTherapeuticTranscriptional RegulationTumor Necrosis Factor-alphaTumor Necrosis FactorsVirusbasecell typechromatin remodelingcytokinegene inductionhuman TNF proteinhuman diseasein vivoinhibitor/antagonistmacrophagenovelpathogenpromoterrelease of sequestered calcium ion into cytoplasmresearch studytranscription factor
项目摘要
DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF) is a key mediator of inflammatory and immune responses produced by many cells including T and B lymphocytes, macrophages and dendritic cells. It is a critical cytokine for eradication of intracellular pathogens such as Mycobacterium tuberculosis (MTb), but uncontrolled can lead to severe disorders such as septic shock, cerebral malaria and autoimmunity. This is illustrated by the efficacy of anti-TNF antibody treatment of rheumatoid arthritis, inflammatory bowel disease and other inflammatory pathologies. TNF is a tightly regulated gene at the level of transcription. Our research has shown that a distinct enhanceosome is recruited to the TNF promoter when macrophage cell lines are stimulated with lipopolysaccharide (LPS) or MTb, distinct from the enhanceosomes recruited to the promoter upon stimulation of T cell lines with virus or calcium. Furthermore, genetic approaches and DNAse I hypersensitivity (DH) analysis in cell lines have identified regulatory elements involved in inducer and cell type specific regulation of the gene outside of the promoter in other non-coding sequences. Based on these findings, our hypothesis is that through a dynamic process of enhanceosome recruitment to the TNF promoter, which contains shared binding sites for distinct activators, together with remodeling of chromatin, the TNF gene achieves both the flexibility and specificity required for its regulation. We will test this hypothesis in primary murine T cells and macrophages in Aims 1 and 2 through the characterization of the chromatin environment of the TNF locus in these cells under different conditions, and by determining the transcription factors and signaling molecules involved in TNF gene expression. In Aim 3, we will examine the chromatin environment and transcription factors involved in the modulation of TNF gene expression by interferon-gamma (IFN-gamma) and interleukin-10 (IL-10). The checkpoints of TNF gene expression will be elucidated using a combination of approaches including: (i) chromatin remodeling by a combination of DH analysis and bioinformatic approaches; (ii) the use of specific inhibitors, RNAi knockdown or mice deficient for candidate transcription factor/signaling molecules; and/or retroviral vectors expressing candidate transcription factors or signalling molecules; (iii) the recruitment of specific TNF enhancer complexes to regulatory elements or the TNF promoter by ChIP analysis of primary cells under different conditions. These experiments will allow us to link the recruitment of specific TNF enhancer complexes with distinct adaptor proteins and subsequent signal transduction pathways. The overarching goals of this proposal are: 1) the identification of specific transcriptional targets allowing for cell and inducer directed therapeutic manipulation of TNF in inflammatory and infectious diseases, and 2) the further elucidation of the mechanisms of control and specificity of eukaryotic gene transcription.
描述(由申请人提供):肿瘤坏死因子(TNF)是由许多细胞(包括T和B淋巴细胞、巨噬细胞和树突细胞)产生的炎症和免疫应答的关键介质。它是根除细胞内病原体如结核分枝杆菌(MTb)的关键细胞因子,但不加控制可导致严重疾病,如败血性休克、脑型疟疾和自身免疫。这通过抗TNF抗体治疗类风湿性关节炎、炎性肠病和其它炎性病理的功效来说明。TNF是一种在转录水平上受到严格调控的基因。我们的研究已经表明,当巨噬细胞系用脂多糖(LPS)或MTb刺激时,一种独特的增强体被募集到TNF启动子,这与用病毒或钙刺激T细胞系时募集到启动子的增强体不同。此外,在细胞系中的遗传方法和DNA酶I超敏性(DH)分析已经鉴定了在其它非编码序列中的启动子之外的基因的诱导物和细胞类型特异性调节中涉及的调节元件。基于这些发现,我们的假设是,通过增强体招聘的TNF启动子,其中包含不同的激活剂,与染色质重塑共享的结合位点的动态过程中,TNF基因实现其调节所需的灵活性和特异性。我们将在目标1和2中的原代鼠T细胞和巨噬细胞中检验这一假设,方法是在不同条件下表征这些细胞中TNF基因座的染色质环境,并确定TNF基因表达所涉及的转录因子和信号分子。在目标3中,我们将研究参与干扰素-γ(IFN-γ)和白细胞介素-10(IL-10)调节TNF基因表达的染色质环境和转录因子。TNF基因表达的检查点将使用方法的组合来阐明,所述方法包括:(i)通过DH分析和生物信息学方法的组合的染色质重塑;(ii)使用特异性抑制剂、RNAi敲低或候选转录因子/信号传导分子缺陷的小鼠;和/或表达候选转录因子或信号传导分子的逆转录病毒载体;(iii)通过在不同条件下对原代细胞进行ChIP分析,将特异性TNF增强子复合物募集至调节元件或TNF启动子。这些实验将使我们能够将特异性TNF增强子复合物的募集与不同的衔接蛋白和随后的信号转导途径联系起来。该提案的总体目标是:1)鉴定特异性转录靶点,从而允许在炎症和感染性疾病中对TNF进行细胞和诱导剂定向的治疗操作,以及2)进一步阐明真核基因转录的控制和特异性机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNE GOLDFELD其他文献
ANNE GOLDFELD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNE GOLDFELD', 18)}}的其他基金
Discovery of novel regulatory territories in the TNF/LT locus
TNF/LT 基因座中新调控区域的发现
- 批准号:
10650771 - 财政年份:2022
- 资助金额:
$ 34.02万 - 项目类别:
Discovery of novel regulatory territories in the TNF/LT locus
TNF/LT 基因座中新调控区域的发现
- 批准号:
10408494 - 财政年份:2022
- 资助金额:
$ 34.02万 - 项目类别:
Immunity to TB in highly immunosuppressed HIV-infected and uninfected individuals
高度免疫抑制的艾滋病毒感染者和未感染者对结核病的免疫力
- 批准号:
9303303 - 财政年份:2016
- 资助金额:
$ 34.02万 - 项目类别:
Immune control mechanisms of TB latency in the setting of HIV co-infection
HIV合并感染情况下结核潜伏期的免疫控制机制
- 批准号:
9229528 - 财政年份:2016
- 资助金额:
$ 34.02万 - 项目类别:
Immunity to TB in highly immunosuppressed HIV-infected and uninfected individuals
高度免疫抑制的艾滋病毒感染者和未感染者对结核病的免疫力
- 批准号:
9205082 - 财政年份:2016
- 资助金额:
$ 34.02万 - 项目类别:
Immune control mechanisms of TB latency in the setting of HIV co-infection
HIV合并感染情况下结核潜伏期的免疫控制机制
- 批准号:
9115843 - 财政年份:2016
- 资助金额:
$ 34.02万 - 项目类别:
Host factors, inflammation, and HIV associated TB
宿主因素、炎症和 HIV 相关结核病
- 批准号:
9114703 - 财政年份:2015
- 资助金额:
$ 34.02万 - 项目类别:
Immune control mechanisms of TB latency in the setting of HIV co-infection
HIV合并感染情况下结核潜伏期的免疫控制机制
- 批准号:
9028020 - 财政年份:2015
- 资助金额:
$ 34.02万 - 项目类别:
T CELL SUBSETS AND THEIR FUNCTION IN TB/HIV PARADOXICAL REACTIONS
T 细胞亚群及其在 TB/HIV 矛盾反应中的功能
- 批准号:
7753855 - 财政年份:2009
- 资助金额:
$ 34.02万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 34.02万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 34.02万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 34.02万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 34.02万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 34.02万 - 项目类别: